Zusammenfassung
Hintergründe zur Pharmakokinetik und zu Interaktionen werden dargestellt. Alle in der Psychopharmakotherapie relevanten Wechselwirkungen werden in Anhang INT und Anhang SUB ausführlich so aufgeführt, dass der Leser die einzelnen Risiken selbst nachvollziehen kann. Der Bezug zu den Angaben bei den einzelnen Präparaten wird hergestellt.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Barski OA, Tipparaju SM, Bhatnagar A (2016) The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev. 40: 553–624
Brückl TM, Uhr M (2016) ABCB1 genotyping in the treatment of depression. Pharmacogenomics 17(18): 2039–2069
Breitenstein B, Scheuer S, Brückl TM et al (2016) Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study. J Psychiatr Res 73: 86–95
Faber MS, Fuhr U (2004) Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 76: 178–184
Gründer G, Baumann P, Conca A et al; für die TDM-Gruppe der AGNP (2014) Therapeutisches Drug-Monitoring in der Psychiatrie. 85: 847855
Haen E (2014) Arzneimittelinteraktionen. Nervenarzt 85: 417–426
Hicks JK, Swen JJ, Thorn CF et al (2013) Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 93: 402–408
Hicks JK, Bishop JR, Sangkuhl K et al; Clinical Pharmacogenetics Implementation Consortium (2015) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther 98: 127–134
Hiemke C, Eckermann G (2014) Kombinationstherapie/Polypharmazie: Interaktionen von Psychopharmaka. Psychopharmakotherapie 21: 269–279
Hiemke C, Bergemann N, Clement HW et al (2018) Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 51: 9–62
Jukić MM, Haslemo T, Molden E et al (2018) Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: a retrospective study based on 2,087 patients. Am J Psychiatry 175: 463–470
Oda S, Fukami T, Yokoi T et al (2015) A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development. Drug Metab Pharmacokinet 30: 30–51
Ostad Haji E, Tadic A, Wagner S et al (2013) Early improvement and serum concentrations of citalopram to predict antidepressant drug response of patients with major depression. Pharmacopsychiatry 46: 261–266
Schatzberg AF, DeBattista, Lazzeroni LC et al (2015) ABCB1 genetic effects on antidepressant outcomes: a report from the iSPOT-D trial. Am J Psychiatry 172: 751–159
Stingl J, Viviani R (2015) Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs. J Intern Med 277(2): 167–177
Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Therapeutics 138: 103–141
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer-Verlag GmbH Deutschland
About this chapter
Cite this chapter
Hiemke, C., Benkert, O. (2019). Pharmakokinetik und Arzneimittelinteraktionen. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57334-1_16
Download citation
DOI: https://doi.org/10.1007/978-3-662-57334-1_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-57333-4
Online ISBN: 978-3-662-57334-1
eBook Packages: Medicine (German Language)